INTRODUCTION: The high mortality and morbidity associated with resection for oesophagogastric malignancy has resulted in a conservative approach to the postoperative management of this patient group. In August 2009 we introduced an enhanced recovery after surgery (ERAS) pathway tailored to patients undergoing resection for oesophagogastric malignancy. We aimed to assess the impact of this change in practice on standard clinical outcomes. METHODS: Two cohorts were studied of patients undergoing resection for oesophagogastric malignancy before (August 2008 - July 2009) and after (August 2009 - July 2010) the implementation of the ERAS pathway. Data were collected on demographics, interventions, length of stay, morbidity and in-hospital mortality. RESULTS: There were 53 and 55 oesophagogastric resections undertaken respectively for malignant disease in each of the study periods. The median length of stay for both gastric and oesophageal resection decreased from 15 to 11 days (Mann-Whitney U, p<0.001) following implementation of the ERAS pathway. There was no significant increase in morbidity (gastric resection 23.1% vs 5.3% and oesophageal resection 25.9% vs 16.7%) or mortality (gastric resection no deaths and oesophageal resection 1.8% vs 3.6%) associated with the changes. There was a significant decrease in the number of oral contrast studies used following oesophageal resection, with a reduction from 21 (77.8%) in 2008-2009 to 6 (16.7%) in 2009-2010 (chi-squared test, p<0.0001). CONCLUSIONS: The introduction of an enhanced recovery programme following oesophagogastric surgery resulted in a significant decrease in length of median patient stay in hospital without a significant increase in associated morbidity and mortality.
INTRODUCTION: The high mortality and morbidity associated with resection for oesophagogastric malignancy has resulted in a conservative approach to the postoperative management of this patient group. In August 2009 we introduced an enhanced recovery after surgery (ERAS) pathway tailored to patients undergoing resection for oesophagogastric malignancy. We aimed to assess the impact of this change in practice on standard clinical outcomes. METHODS: Two cohorts were studied of patients undergoing resection for oesophagogastric malignancy before (August 2008 - July 2009) and after (August 2009 - July 2010) the implementation of the ERAS pathway. Data were collected on demographics, interventions, length of stay, morbidity and in-hospital mortality. RESULTS: There were 53 and 55 oesophagogastric resections undertaken respectively for malignant disease in each of the study periods. The median length of stay for both gastric and oesophageal resection decreased from 15 to 11 days (Mann-Whitney U, p<0.001) following implementation of the ERAS pathway. There was no significant increase in morbidity (gastric resection 23.1% vs 5.3% and oesophageal resection 25.9% vs 16.7%) or mortality (gastric resection no deaths and oesophageal resection 1.8% vs 3.6%) associated with the changes. There was a significant decrease in the number of oral contrast studies used following oesophageal resection, with a reduction from 21 (77.8%) in 2008-2009 to 6 (16.7%) in 2009-2010 (chi-squared test, p<0.0001). CONCLUSIONS: The introduction of an enhanced recovery programme following oesophagogastric surgery resulted in a significant decrease in length of median patient stay in hospital without a significant increase in associated morbidity and mortality.
Authors: G Brodner; E Pogatzki; H Van Aken; H Buerkle; C Goeters; C Schulzki; H Nottberg; N Mertes Journal: Anesth Analg Date: 1998-02 Impact factor: 5.108
Authors: Donald E Low; Sonia Kunz; Drew Schembre; Henry Otero; Tom Malpass; Alex Hsi; Guobin Song; Richard Hinke; Richard A Kozarek Journal: J Gastrointest Surg Date: 2007-08-31 Impact factor: 3.452
Authors: Robert James Cerfolio; Ayesha S Bryant; Cynthia S Bass; Jeana R Alexander; Alfred A Bartolucci Journal: Chest Date: 2004-10 Impact factor: 9.410
Authors: Gijs H Berkelmans; Frans van Workum; Teus J Weijs; Grard A Nieuwenhuijzen; Jelle P Ruurda; Ewout A Kouwenhoven; Marc J van Det; Camiel Rosman; Richard van Hillegersberg; Misha D Luyer Journal: J Thorac Dis Date: 2017-07 Impact factor: 2.895
Authors: Michael Hughes; Ivan Yim; D A Christopher Deans; Graeme W Couper; Peter J Lamb; Richard J E Skipworth Journal: World J Surg Date: 2018-01 Impact factor: 3.352
Authors: Jitesh B Shewale; Arlene M Correa; Carla M Baker; Nicole Villafane-Ferriol; Wayne L Hofstetter; Victoria S Jordan; Henrik Kehlet; Katie M Lewis; Reza J Mehran; Barbara L Summers; Diane Schaub; Sonia A Wilks; Stephen G Swisher Journal: Ann Surg Date: 2015-06 Impact factor: 12.969
Authors: Bang Wool Eom; Jungnam Joo; Young-Woo Kim; Boram Park; Hong Man Yoon; Keun Won Ryu; Soo Jin Kim Journal: J Gastric Cancer Date: 2015-12-31 Impact factor: 3.720